Prometheus Laboratories has forged a collaboration with Fresenius Kabi to support the validation of Anser therapeutic drug monitoring (TDM) services as well as its access to qualified patients receiving the latter’s biosimilar IDACIO (adalimumab-aacf).
According to Prometheus Laboratories, Anser is a range of homogenous mobility shift tests. The assays are utilised to optimise biologic and biosimilar therapy in autoimmune diseases.
Anser TDM services are said to be useful for clinicians who treat immune-mediated conditions like inflammatory bowel disease (IBD) and rheumatoid arthritis (RA). They help them to obtain objective data that can guide treatment decisions.
The partnership will also include the Fresenius Kabi biosimilars for tocilizumab and ustekinumab when they are released in the market.
Prometheus Laboratories president Mike Walther said: “We applaud Fresenius Kabi in their forward-thinking approach to patient care.
“At Prometheus we are driven to make a meaningful difference in the lives of patients through precision medicine and are proud to work with collaborators who share our mission to help transform patient care.”
The US-based speciality clinical laboratory claimed that TDM has been shown as a useful and effective tool for optimising treatment management strategies.
It is useful for patients who demonstrated no response or who may lose response over time during treatment of immune-mediated diseases using biologics.
Anser, which was first launched in 2012, measures the levels of biologic drug and antidrug antibody in serum.
Currently, TDM services are available to monitor therapeutic drugs like adalimumab, infliximab, vedolizumab, and ustekinumab.
Altoona Center for Clinical Research and Altoona Arthritis and Osteoporosis Center founder and medical director Alan Kivitz said: “There is evidence on the clinical and health economic value of therapeutic drug monitoring for biologics and biosimilars in autoimmune diseases.
“The availability of Anser testing for an adalimumab biosimilar like Idacio will be a welcome addition to the care protocol of our Rheumatoid Arthritis patients.”
Recently, Prometheus Laboratories introduced its precision-guided PredictrPK ADA dosing test for the optimisation of adalimumab therapy.
